Entero Therapeutics Inc. (ENTO) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Entero Therapeutics Inc. (ENTO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.59

0.00 (0.20%)

At close: Jan 14, 2025, 3:58 PM

0.56

-5.85%

After-hours Jan 14, 2025, 03:59 PM EST

undefined% (undefined)

Bid	0.45
Market Cap	2.80M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	14.17
PE Ratio (ttm)	0.04
Forward PE	n/a
Analyst	n/a

Ask	0.7
Volume	21,238
Avg. Volume (20D)	260,278
Open	0.54
Previous Close	0.59
Day's Range	0.54 - 0.59
52-Week Range	0.18 - 9.35
Beta	undefined

About ENTO

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides; biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Oct 11, 2016

Employees 9

Stock Exchange NASDAQ

Ticker Symbol ENTO

Website https://www.firstwavebio.com

Why Price Moved

2 months ago · Source

+1.61%

Entero Therapeutics shares are trading lower. The ... Unlock content with Pro Subscription

News

2 months ago · businesswire.com

ENTERO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Entero Therapeutics, Inc. - ENTO

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Entero Therape...

2 months ago · businesswire.com

Shareholder Alert: Ademi LLP Investigates Whether Entero Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Entero (Nasdaq: ENTO) for possible breaches of fiduciary duty and other violations of law in its transaction with Journey. Click here to learn ho...

2 months ago · businesswire.com

ENTO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Entero Therapeutics, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Entero Therapeutics, Inc. (NASDAQ: ENTO) and Journey Therapeutics, Inc. is fair to Ente...